Patricia Irene Dickson MD
Clinical Genetics, Medical Biochemical Genetics, Pediatric Medical Genetics
Centennial Professor of Pediatrics and Genetics Chief of the Division of Genetics and Genomic Medicine Washington University in St. Louis School of Medicine
Join to View Full Profile
1 Childrens Pl# DivSaint Louis, MO 63110
Phone+1 314-454-6093
Fax+1 844-965-9624
Dr. Dickson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cedars-Sinai Medical CenterResidency, Medical Genetics and Genomics, 2003 - 2007
Los Angeles County-Harbor-UCLA Medical CenterResidency, Pediatrics, 1999 - 2003
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999, MD
Certifications & Licensure
IL State Medical License 2021 - 2026
MO State Medical License 2018 - 2025
CA State Medical License 2000 - 2020
American Board of Medical Genetics and Genomics Clinical Genetics- American Board of Medical Genetics and Genomics Medical Biochemical Genetics
American Board of Pediatrics Pediatrics
Clinical Trials
- Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I Start of enrollment: 2005 Nov 01
- Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I Start of enrollment: 2008 Jan 01
- A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I Start of enrollment: 2009 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice.Sarah C Hurt, Steven Q Le, Shih-Hsin Kan, Quang D Bui, Michael D Brodt
Molecular Therapy. Methods & Clinical Development. 2025-03-13 - 1 citationsCommunity consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses.Joseph Muenzer, Carole Ho, Heather Lau, Mark Dant, Maria Fuller
Molecular Genetics and Metabolism. 2024-08-01 - 4 citationsD-mannose as a new therapy for fucokinase deficiency-related congenital disorder of glycosylation (FCSK-CDG).Rodrigo Tzovenos Starosta, Angela J Lee, Elizabeth R Toolan, Miao He, Parith Wongkittichote
Molecular Genetics and Metabolism. 2024-06-01
Press Mentions
Undiagnosed Diseases Clinic Expands Outreach to Underserved CommunitiesFebruary 20th, 2025- WashU Medicine Launches Center for Rare DiseasesFebruary 14th, 2025
- Yes, Men Can Get Breast Cancer, Too. Here’s Who Is Most at RiskOctober 31st, 2022
- Join now to see all
Grant Support
- Systems-Level Approach to Neuronopathic Lysosomal Storage DisordersWASHINGTON UNIVERSITY2023–2028
- Systems-Level Approach to Neuronopathic Lysosomal Storage DisordersWASHINGTON UNIVERSITY2023–2028
- Cellular Phenotypes of Genetic Variants in MucopolysaccharidosisWASHINGTON UNIVERSITY2023–2028
- Systems-Level Approach to Neuronopathic Lysosomal Storage DisordersWASHINGTON UNIVERSITY2023–2028
- Systems-Level Approach to Neuronopathic Lysosomal Storage DisordersWASHINGTON UNIVERSITY2023–2028
- Washington University in St. Louis UDN Diagnostic Center of ExcellenceWASHINGTON UNIVERSITY2018–2028
- Washington University in St. Louis UDN Diagnostic Center of ExcellenceWASHINGTON UNIVERSITY2018–2028
- Washington University in St. Louis UDN Diagnostic Center of ExcellenceWASHINGTON UNIVERSITY2018–2028
- Washington University in St. Louis UDN Diagnostic Center of ExcellenceWASHINGTON UNIVERSITY2018–2028
- Postdoctoral Training Program in Genomic MedicineWASHINGTON UNIVERSITY2021–2026
- Postdoctoral Training Program in Genomic MedicineWASHINGTON UNIVERSITY2021–2026
- Postdoctoral Training Program in Genomic MedicineWASHINGTON UNIVERSITY2021–2026
- Postdoctoral Training Program in Genomic MedicineWASHINGTON UNIVERSITY2021–2026
- Intravenous delivery of 2-hydroxypropyl-Beta-cyclodextrin for treatment of Niemann-Pick C diseaseWASHINGTON UNIVERSITY2017–2025
- Development and Validation of Therapy for Mucopolysaccharidosis IIIPHOENIX NEST, INC.2014–2025
- Intrathecal Enzyme Therapy For Mucopolysaccharidosis INational Institute Of Neurological Disorders And Stroke2006–2010
- Pilot/Phase I Study Of Intrathecal Laronidase For Spinal Cord Compression In MucoFood And Drug Administration2008–2009
- A Study Of Intrathecal Enzyme Replacement Therapy For Spinal Cord CompressionNational Center For Research Resources2006–2009
- Clinical Trial: A Study Of Intrathecal Enzyme Replacement Therapy For Spinal CORNational Center For Research Resources2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
